| Literature DB >> 23193486 |
Rebeca Ramis1, Pablo Fernandez-Navarro, Javier Garcia-Perez, Elena Boldo, Diana Gomez-Barroso, Gonzalo Lopez-Abente.
Abstract
Spatial aggregation of different industrial facilities leads to simultaneous release of pollutant emissions. Our objective is to study cancer mortality risk associated with residence in the vicinity of pollutant factories. We used data on industries for year 2007 (3458 facilities). For the 8,098 Spanish towns, we defined a factor with 4 levels based on the number of factories in a radius of 2.5 km from the centroid of each town (industrial factor). We also used data of land cover use to approximate the percentage of municipal land used for industrial activities in each Spanish town (land-used variable). For both variables we fitted Poisson models with random terms to account for spatial variation. We estimated risk trends related with increasing number of factories or percentage of land used for industrial activities. We studied 33 cancer causes. For the industrial factor, 11 causes showed trend associated with increasing factor level. For the land use variable, 8 causes showed statistically significant risks. Almost all tumours related to the digestive system and the respiratory system showed increased risks. Thus mortality by these tumours could be associated to residence in towns nearby industrial areas with positive trend linked to increasing levels of industrial activity.Entities:
Year: 2012 PMID: 23193486 PMCID: PMC3463942 DOI: 10.5402/2012/614198
Source DB: PubMed Journal: ISRN Oncol ISSN: 2090-5661
Figure 1Map with the location of 3458 industrial facilities in black dots.
Figure 2Examples of locations of facilities around towns. Blue dots are the towns centroid. Green rings are the 2.5 km buffer centred in the town centroid. Small black rings are the industrial facilities. Red lines link facilities that are at most 500 m apart from each other.
Number of deaths for 33 cancer causes, ICD 9 and ICD 10 code, women, men and total, Spain, 1997–2006.
| Tumours | ICD 9 | ICD 10 | Women | Men | Total |
|---|---|---|---|---|---|
| Buccal cavity and pharynx | 140–149 | C00–14 | 3,842 | 18,136 | 21,978 |
| Esophagus | 150 | C15 | 2,383 | 15,377 | 17,760 |
| Stomach | 151 | C16 | 22,917 | 36,754 | 59,671 |
| Small intestine | 152 | C17 | 620 | 744 | 1,364 |
| Colon-rectum | 153-154 | C18–20 | 52,746 | 68,095 | 120,841 |
| Liver | 155 | C22 | 6,646 | 17,609 | 24,255 |
| Gall-bladder | 156 | C23 | 8,785 | 4,682 | 13,467 |
| Pancreas | 157 | C25 | 19,590 | 22,328 | 41,918 |
| Peritoneum | 158 | C45.1, C48 | 1,281 | 1,066 | 2,347 |
| Nasal fossae | 160 | C30, C31 | 272 | 636 | 908 |
| Larynx | 161 | C32 | 623 | 16,674 | 17,297 |
| Lung | 162 | C34 | 20,923 | 160,104 | 181,027 |
| Pleura | 163 | C38.4, C45.0 | 618 | 1,538 | 2,156 |
| Bones | 170 | C40 | 1,219 | 1,702 | 2,921 |
| Connective tissue | 171 | C41 | 2,034 | 2,148 | 4,182 |
| Melanoma | 172 | C43 | 3,414 | 3,987 | 7,401 |
| Skin | 173 | C44, C46 | 2,134 | 2,498 | 4,632 |
| Breast | 174 | C50 | 57,830 | 57,830 | |
| Other uterus | 179–181 | C53-54 | 3,355 | 3,355 | |
| Uterus | 182 | C55 | 18,080 | 18,080 | |
| Ovary | 183 | C56 | 18,046 | 18,046 | |
| Prostate | 185 | C61 | 55,772 | 55,772 | |
| Testis | 186 | C62 | 425 | 425 | |
| Bladder | 188 | C67 | 7,175 | 34,107 | 41,282 |
| Kidney | 189 | C64 | 5,809 | 11,532 | 17,341 |
| Brain | 191 | C71 | 10,067 | 12,622 | 22,689 |
| Other tumours nervous sys | 191 | C72 | 401 | 400 | 801 |
| Thyroid | 193 | C73 | 1,800 | 911 | 2,711 |
| Ill-defined tumours | 195–199 | C76–C80, C96 | 26,670 | 33,968 | 60,638 |
| Non-Hodgkin's lymphoma | 200, 202 | C82–84 | 11,109 | 12,229 | 23,338 |
| Hodgkin's | 201 | C81 | 1,034 | 1,345 | 2,379 |
| Myeloma | 203 | C90 | 7,637 | 7,541 | 15,178 |
| Leukemias | 204–208 | C91–95 | 12,775 | 16,295 | 29,070 |
|
| |||||
| Total | 140–208 | C00–C97 | 331,835 | 561,225 | 893,060 |
Industry levels, number of facilities, number of towns within the radius, population.
| Level | No. facilities | Towns | Population |
|---|---|---|---|
| L0 | 0 | 6894 (85.13%) | 22890314 (56.95%) |
| L1 | 1 | 630 (7.78%) | 6344330 (15.78%) |
| L2 | 2 | 228 (2.82%) | 3318915 (8.26%) |
| L2 | 3 | 121 (1.49%) | 2684455 (6.68%) |
| L2 | 4 | 64 (0.79%) | 1062607 (2.64%) |
| L3 | 5 | 41 (0.51%) | 847854 (2.11%) |
| L3 | 6 | 32 (0.40%) | 771036 (1.92%) |
| L3 | 7 | 17 (0.21%) | 209541 (0.52%) |
| L3 | 8 | 21 (0.26%) | 324714 (0.81%) |
| L3 | 9 | 6 (0.07%) | 62709 (0.16%) |
| L3 | 10 | 8 (0.10%) | 347082 (0.86%) |
| L3 | 11 | 9 (0.11%) | 181530 (0.45%) |
| L3 | 12 | 7 (0.09%) | 449401 (1.12%) |
| L3 | 13 | 2 (0.02%) | 35078 (0.09%) |
| L3 | 14 | 4 (0.04%) | 163150 (0.41%) |
| L3 | 15 | 4 (0.04%) | 331421 (0.82%) |
| L3 | 16 | 3 (0.04%) | 101026 (0.25%) |
| L3 | 18 | 3 (0.01%) | 15151 (0.04%) |
| L3 | 25 | 1 (0.01%) | 18854 (0.05%) |
| L3 | 27 | 1 (0.01%) | 8934 (0.02%) |
| L3 | 28 | 1 (0.01%) | 7269 (0.02%) |
| L3 | 55 | 1 (0.01%) | 17482 (0.04%) |
|
| |||
|
| Total | 8098 (100%) | 40192853 (100%) |
Trend test results. Trend and credible intervals.
| Tumours | All | Women | Men | |||
|---|---|---|---|---|---|---|
| Trend | (2.5%, 97.5%) | Trend | (2.5%, 97.5%) | Trend | (2.5%, 97.5%) | |
| Buccal cavity and pharynx |
|
| 0.98 | (0.95, 1.02) |
|
|
| Esophagus |
|
| 0.99 | (0.93, 1.04) |
|
|
| Stomach |
|
| 1 | (0.98, 1.02) |
|
|
| Small intestine* | 0.96 | (0.89, 1.03) | 0.99 | (0.90, 1.08) | 0.97 | (0.89, 1.05) |
| Colon-Rectum |
|
|
|
|
|
|
| Liver |
|
| 1.03 | (0.99, 1.08) |
|
|
| Gall-Bladder |
|
| 1.01 | (0.98, 1.04) |
|
|
| Pancreas | 1 | (0.99, 1.02) | 0.99 | (0.98, 1.01) | 1 | (0.99, 1.02) |
| Peritoneum* | 1.03 | (0.98, 1.08) | 1.03 | (0.97, 1.10) | 1.03 | (0.96, 1.11) |
| Nasal fossae* | 0.99 | (0.93, 1.07) | 0.96 | (0.84, 1.09) | 1.01 | (0.92, 1.10) |
| Larynx | 1.01 | (0.99, 1.04) | 0.99 | (0.91, 1.09) | 1.01 | (0.99, 1.04) |
| Lung |
|
| 0.97 | (0.95, 0.99) |
|
|
| Pleura* |
|
|
|
|
|
|
| Bones | 0.97 | (0.93, 1.01) | 1.02 | (0.96, 1.09) | 0.94 | (0.89, 0.99) |
| Connective tissue* | 1.01 | (0.97, 1.05) | 0.99 | (0.94, 1.05) | 1.02 | (0.98, 1.07) |
| Melanoma | 0.96 | (0.94, 0.99) | 0.96 | (0.92, 1.00) | 0.97 | (0.93, 1.00) |
| Skin | 0.93 | (0.89, 0.97) | 0.93 | (0.88, 0.99) | 0.94 | (0.89, 0.99) |
| Breast | 1 | (0.99, 1.01) | ||||
| Other uterus* | 1.02 | (0.98, 1.06) | ||||
| Uterus | 0.98 | (0.95, 1.00) | ||||
| Ovary | 1.01 | (0.99, 1.03) | ||||
| Prostate | 0.99 | (0.98, 1.01) | ||||
| Testis* | 1 | (0.98, 1.01) | ||||
| Bladder |
|
| 1.01 | (0.98, 1.04) |
|
|
| Kidney |
|
|
|
|
|
|
| Brain |
|
|
|
| 0.99 | (0.97, 1.01) |
| Other tumours nervous sys* | 0.99 | (0.91, 1.07) | 1 | (0.89, 1.12) | 0.98 | (0.88, 1.09) |
| Thyroid | 1.01 | (0.96, 1.06) | 1.02 | (0.97, 1.08) | 0.99 | (0.92, 1.06) |
| Ill-defined tumours |
|
| 1 | (0.98, 1.01) |
|
|
| Non-Hodgkin's lymphomas | 1.01 | (0.99, 1.03) | 1 | (0.98, 1.03) | 1.01 | (0.98, 1.03) |
| Hodgkings* | 0.98 | (0.94, 1.03) | 0.99 | (0.93, 1.06) | 0.97 | (0.92, 1.03) |
| Myeloma* | 1.01 | (0.99, 1.03) | 1.02 | (0.99, 1.04) | 1 | (0.98, 1.03) |
| Leukemias |
|
| 1.02 | (0.99, 1.04) |
|
|
*Indicates if the fitted model was the Mixed model.
Figure 3Graphs for the causes that showed trend. Each line resents each of the population groups: black line is for the total population (All), red line is for women, and green for men.
Relative risks and credible intervals of the variable of land use.
| Tumours | All | Women | Men | |||
|---|---|---|---|---|---|---|
| RR | (2.5%, 97.5%) | RR | (2.5%, 97.5%) | RR | (2.5%, 97.5%) | |
| Stomach |
|
| 1.01 | (0.98, 1.04) |
|
|
| Liver |
|
| 1.06 | (0.99, 1.14) |
|
|
| Lung |
|
| 0.98 | (0.94, 1.02) |
|
|
| Pleura* |
|
|
|
|
|
|
| Breast |
|
| ||||
| Bladder |
|
| 1.01 | (0.96, 1.06) |
|
|
| Ill-defined tumours | 1.02 | (0.99, 1.04) | 0.99 | (0.96, 1.02) |
|
|
| Non-Hodgking's lymphomas |
|
| 1.03 | (0.99, 1.08) |
|
|
| Leukemias |
|
|
|
|
|
|
*Indicates if the fitted model was the Mixed mode.